Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin
- 1 June 1992
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 339 (8807), 1476
- https://doi.org/10.1016/0140-6736(92)92064-m
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1992
- Inhibition of Development of Kaposi's Sarcoma-Related Lesions by a Bacterial Cell Wall ComplexScience, 1992
- Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosisThe Lancet, 1992
- Low molecular weight heparinBlood, 1992
- Anionic Dyes, Heparin, and Heparinoids: The Rediscovery of Polyanionic Tumor InhibitorsJNCI Journal of the National Cancer Institute, 1989
- Suramin: an anticancer drug with a unique mechanism of action.Journal of Clinical Oncology, 1989
- Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoidJournal of Vascular Surgery, 1988
- Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of CortisoneScience, 1983
- Suppression by heparin of smooth muscle cell proliferation in injured arteriesNature, 1977